Nortriptyline E-10-Hydroxylation in Vitro Is Mediated by Human CYP2D6 (High Affinity) and CYP3A4 (Low Affinity): Implications for Interactions with Enzyme-Inducing Drugs-Reference-Cited by-同舟云学术

Nortriptyline E-10-Hydroxylation in Vitro Is Mediated by Human CYP2D6 (High Affinity) and CYP3A4 (Low Affinity): Implications for Interactions with Enzyme-Inducing Drugs

Published:1999-06 Issue:6 Volume:39 Page:567-577
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Venkatakrishnan Karthik,von Moltke Lisa L.,Greenblatt David J.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference37 articles.

1. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression;Reynolds;JAMA,1999

2. E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation;Mellström;Clin Pharmacol Ther,1981

3. Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects;Woolhouse;Clin Pharmacol Ther,1984

4. 10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes;Dalén;Clin Pharmacol Ther,1998

5. Stereo-selective inhibition of nortriptyline hydroxylation in man by quinidine;Pfandl;Xenobiotica,1992

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics and Safety of Atogepant Co‐administered with Quinidine Gluconate in Healthy Participants: A Phase 1, Open‐Label, Drug‐Drug Interaction Study;Clinical Pharmacology in Drug Development;2024-05-03

2. An Overview of Various Rifampicin Analogs against Mycobacterium tuberculosis and their Drug Interactions;Medicinal Chemistry;2023-10-05

3. Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients;Acta Pharmaceutica Sinica B;2023-01

4. Precision Medicine in Antidepressants Treatment;Precision Medicine;2023

5. DeepFusion: A deep learning based multi-scale feature fusion method for predicting drug-target interactions;Methods;2022-08